Anti-CD44 Monoclonal Antibody (Clone:IHC044)
|Amount :||1 ml|
|Purification :||Protein A/G Chromatography|
|Storage condition :||Store at 2°C - 8°C.|
|Gene ID :||960|
|Uniprot ID :||P16070|
|Alternative Name :||LHR, MDU2, MDU3, MIC4, CD44 antigen, CDw44, Epican, Extracellular matrix receptor III, ECMR-III, GP90 lymphocyte homing/adhesion receptor, HUTCH-I, Heparan sulfate proteoglycan, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, Phagocytic glycoprotein I, PGP-I|
Cluster of differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid, which plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Studies have suggested that the CD44-hyaluronate interaction is central to tumor invasiveness. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as Non-Hodgkins Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumors. It has also been demonstrated that there is a positive correlation between tumor progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma in situ from non-neoplastic changes in the urothelium.
Recommended dilutions: Immunohistochemical analysis: 1:100 - 1:200. However, this need to be optimized based on the research applications.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.